ArticleHaematologica2025

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.

Yousef Laham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.